Safety Compliance

Business

Korro Bio Unveils RNA-Editing Therapy KRRO-121, Aiming to Redefine Ammonia Control for Rare Metabolic and Liver Disorders

At its Analyst Day, Korro Bio detailed its lead candidate KRRO-121, an RNA-editing therapeutic designed to tackle hyperammonemia in urea cycle disorders and hepatic encephalopathy by stabilizing a key liver enzyme, positioning it as a potential paradigm shift from current burdensome treatments.

Jan 30, 2026

Business

Valero Energy Caps Record Year with Soaring Q4 Profits, Eyes Policy Shifts and Venezuelan Crude

Valero Energy reported a robust fourth quarter, with net income surging to $1.1 billion, driven by strong refining margins and record operational performance. While renewable diesel faced headwinds, ethanol profits soared. The company outlined disciplined capital plans and highlighted potential tailwinds from policy clarity and increased access to discounted heavy crude.

Jan 30, 2026

Business

Unity Integrates Coda for Direct Web Stores, Aiming to Reshape Developer Monetization

Unity Software's new in-app web store integration with Coda could empower developers to bypass traditional marketplace fees, potentially altering the company's revenue streams and addressing its persistent valuation gap amid volatile stock performance.

Jan 30, 2026

Business

Bitcoin's Luster Fades Against Gold, Revisiting 2017 Ratio as Debate Over Digital Haven Intensifies

The Bitcoin-to-gold ratio has slumped close to its 2017 level, fueling a fresh round of scrutiny over the cryptocurrency's viability as a long-term store of value amidst a resurgent precious metals market and persistent macroeconomic uncertainty.

Jan 30, 2026

Business

United Rentals Caps Record 2025, Eyes Another Year of Growth Fueled by Mega-Projects

United Rentals reported strong Q4 results, driven by data center and power sector demand, and issued 2026 guidance forecasting continued revenue growth. Management highlighted a robust project pipeline while navigating margin pressures.

Jan 30, 2026

Business

Thermo Fisher Scientific Caps 'Strong Year' with Robust Q4, Eyes Strategic Growth Amid Market Headwinds

Thermo Fisher Scientific reported a strong finish to 2025, with Q4 results exceeding expectations. While navigating currency volatility and tariffs, the life sciences giant highlighted growth in core biopharma sectors, strategic acquisitions like Clario, and a solid 2026 outlook.

Jan 30, 2026

Business

Regulatory Headwinds Cloud Outlook for PDD Holdings Amid Broader China Internet Crackdown

While Morgan Stanley maintains an Overweight rating on PDD Holdings, the firm has removed the e-commerce giant from its Top Picks list, citing heightened regulatory scrutiny and a slower-than-expected consumer recovery in China.

Jan 30, 2026

Business

Bargain Hunt: UK Stocks Trading at Steep Discounts Amid Market Jitters

As the FTSE indices reel from weak Chinese trade data, a screen of undervalued UK equities reveals potential opportunities. We examine three companies trading significantly below their estimated cash flow value.

Jan 30, 2026

Business

Navigating the Maze: A Self-Employed Guide to Tax and National Insurance as Digital Overhaul Looms

With the annual self-assessment deadline a perennial source of stress for freelancers and sole traders, this guide breaks down the essentials of income tax and National Insurance. The landscape is set for a significant shift with the incoming Making Tax Digital regime, making this a crucial year to get to grips with the current rules.

Jan 30, 2026

Business

China Approves Sciwind's Diabetes Drug Xianyida, Intensifying GLP-1 Market Competition

Sciwind Biosciences secures Chinese approval for its GLP-1 agonist Xianyida, entering a crowded but high-stakes diabetes treatment market dominated by global giants, as the country grapples with the world's largest diabetic population.

Jan 30, 2026

Business

Parker-Hannifin Soars on Record Q2, Raises Outlook Amid Filtration Group Deal Progress

Parker-Hannifin posts record-breaking Q2 fiscal 2026 results, fueled by robust organic growth and margin expansion, particularly in aerospace. The industrial giant raises full-year guidance and details strategic progress on its planned acquisition of Filtration Group Corporation.

Jan 30, 2026

Business

Janus Henderson Group: A Valuation Crossroads as Analysts Clash on Fair Price

Janus Henderson Group (NYSE:JHG) finds itself at the center of a valuation debate. While some models peg the asset manager as modestly undervalued, a deeper cash flow analysis suggests a starkly different picture, leaving investors to weigh competing narratives amid industry headwinds.

Jan 30, 2026

Business

U.S. Antimony Shares Tumble as Policy Shift Clouds Expansion Ambitions

United States Antimony (UAMY) faces a volatile market reaction following Washington's reported reversal on critical mineral price supports, casting uncertainty over its strategic expansion into Bolivia.

Jan 30, 2026

Business

Crypto Rout Ripples Through Corporate Treasuries: MicroStrategy and BitMine Shares Tumble

A sharp downturn in cryptocurrency markets has spilled over into the stocks of major corporate holders, with MicroStrategy and BitMine leading losses as their aggressive accumulation strategies face mounting pressure.

Jan 30, 2026

Business

Gold's Meteoric Rise: Safe Haven or Speculative Frenzy?

Gold prices have surged past $5,500, driven by geopolitical tensions and fiscal fears. Yet, analysts caution that its reputation as a stable store of value may be overstated, pointing to inherent volatility and shifting market dynamics.

Jan 30, 2026

Business

UBS Bets Big on Biotech Turnaround, Initiates Arcellx Coverage with $100 Target

UBS has launched coverage of Arcellx with a Buy rating and a $100 price target, signaling growing Wall Street confidence in a biotech sector recovery and spotlighting the company's promising CAR-T therapy for multiple myeloma.

Jan 30, 2026

Business

Mineralys Therapeutics Submits New Drug Application for Hypertension Treatment Lorundrostat, Backed by Strong Clinical Data

Clinical-stage biopharma Mineralys Therapeutics has filed its New Drug Application for lorundrostat, a potential treatment for resistant hypertension, following positive results from multiple trials. The move positions the company for a potential 2026 market entry and has drawn upgraded price targets from analysts.

Jan 30, 2026

Business

International Seaways Charts New Course: Fleet Reshuffle and Full Tankers International Takeover Fuel Valuation Debate

International Seaways (INSW) is aggressively repositioning its fleet, securing full control of Tankers International and selling older vessels. As its stock surges, analysts are divided on whether the strategic moves have already been priced in or if significant upside remains.

Jan 30, 2026

Business

Analysis: Asian Equities Trading at Steep Discounts, With Some Stocks Undervalued by Over 25%

Amidst global market turbulence, a new screen reveals a significant number of Asian stocks are trading below their intrinsic value, with discounts as high as 26.4%. We examine three standout companies from South Korea, Thailand, and Japan that appear poised for a potential re-rating.

Jan 30, 2026

Business

Beyond the Headlines: Unearthing Small-Cap Opportunities in Asia's Volatile 2026 Markets

Amidst a complex backdrop of economic crosscurrents and geopolitical tensions, a select group of small-cap companies across Asia are demonstrating remarkable resilience and growth potential. We analyze three standout names from Singapore and China that are navigating the volatility with strong fundamentals.

Jan 30, 2026